WASHINGTON (dpa-AFX) – Geron Corp. (GERN) announced the FDA has assigned a standard review and a Prescription Drug User Fee Act action date of June 16, 2024 for New Drug Application for imetelstat for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes. Also, the FDA informed…Read More
Geron FDA Assigns PDUFA Action Date For NDA For Imetelstat
